Latest Period
Q2 2026
Security Snapshot
Insight Molecular Diagnostics Inc. - Common Stock, no par value (IMDX) Institutional Ownership
CUSIP: 68235C206
13F Institutional Holders and Ownership History from Q2 2023 to Q2 2026
Institutions Reporting
40
Shares (Excl. Options)
18,464,409
Price
$5.90
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, no par value
- Symbol
- IMDX on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 18,464,409
- Total 13F value
- $108,940,542
- Portfolio coverage rank
- 0%
- Share change
- -479,427
- Value change
- +$995,315
- Number of holders
- 40
- Shares outstanding
- 32,330,312
- SEC-reported price per share
- $4.74
- Insider filing price
- $4.74
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- IMDX - Insight Molecular Diagnostics Inc. - Common Stock, no par value is tracked under CUSIP 68235C206.
- 40 institutions reported positions in Q2 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 41 to 40 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $62,116,945 to $108,940,542.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 40 institutions filings for Q2 2026.
Security key
68235C206
Latest holder period
Q2 2026
13F holders
40
13D/G owners
2
CIK / CUSIP context first
Open Q2 2026 holders
IMDX full holder history
Insight Molecular Diagnostics Inc. SEC filings
Insight Molecular Diagnostics Inc. company facts
Insight Molecular Diagnostics Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 68235C206:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
2
Security
IMDX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BROADWOOD PARTNERS, L.P. | 40% | +6.2% | $41,828,418 | +$2,454,098 | 12,835,134 | +6.2% | Neal C. Bradsher | 23 Apr 2026 |
| AWM Investment Company, Inc. | 10% | +31% | $9,685,464 | +$5,257,076 | 2,857,069 | +119% | AWM Investment Company, Inc. | 31 Mar 2025 |
As of 30 Jun 2026, 40 institutional investors reported holding 18,464,409 shares of Insight Molecular Diagnostics Inc. - Common Stock, no par value (IMDX). This represents 57% of the company’s total 32,330,312 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
57%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BROADWOOD CAPITAL INC | 39% | 12,684,884 | +6.3% | 3.9% | $74,840,816 |
| AWM Investment Company, Inc. | 8.8% | 2,836,692 | +1.1% | 1.5% | $16,736,483 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.3% | 735,847 | +37% | 0% | $4,341,497 |
| PURA VIDA INVESTMENTS, LLC | 1.5% | 484,845 | -49% | 7.7% | $2,860,585 |
| Family Office Research LLC | 1.1% | 368,849 | +190% | 0.82% | $2,176,207 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.79% | 256,903 | -2% | 0% | $1,516,953 |
| FNY Investment Advisers, LLC | 0.56% | 182,561 | -26% | 0.39% | $1,077,000 |
| JANE STREET GROUP, LLC | 0.49% | 157,682 | 0% | $930,324 | |
| BlackRock, Inc. | 0.47% | 150,521 | +11% | 0% | $888,074 |
| VANGUARD FIDUCIARY TRUST CO | 0.39% | 124,576 | -6% | 0% | $734,998 |
| STATE STREET CORP | 0.28% | 92,124 | +82% | 0% | $543,532 |
| MILLENNIUM MANAGEMENT LLC | 0.26% | 82,499 | -20% | 0% | $486,744 |
| UBS Group AG | 0.16% | 53,276 | +134% | 0% | $314,329 |
| NORTHERN TRUST CORP | 0.15% | 49,090 | 0% | 0% | $289,631 |
| OSAIC HOLDINGS, INC. | 0.12% | 39,136 | +62% | 0% | $230,901 |
| MORGAN STANLEY | 0.11% | 35,515 | -1.6% | 0% | $209,539 |
| Jefferies Financial Group Inc. | 0.06% | 18,100 | 0% | $106,790 | |
| MARSHALL WACE, LLP | 0.05% | 16,597 | 0% | $97,922 | |
| ExodusPoint Capital Management, LP | 0.04% | 14,029 | 0% | $82,771 | |
| AXQ CAPITAL, LP | 0.04% | 13,407 | 0.01% | $79,101 | |
| Flatrock Wealth Partners LLC | 0.04% | 13,044 | 0% | 0.03% | $76,960 |
| TWO SIGMA INVESTMENTS, LP | 0.03% | 11,101 | 0% | $65,496 | |
| XTX Topco Ltd | 0.03% | 10,743 | -65% | 0% | $63,384 |
| Private Advisor Group, LLC | 0.03% | 10,416 | 0% | 0% | $61,454 |
| BNP PARIBAS FINANCIAL MARKETS | 0.02% | 5,801 | 0% | 0% | $34,226 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
13
Latest
Q2 2026
Rows shown
1-13 of 13
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 18,464,409 | $108,940,542 | +$995,315 | $5.90 | 40 |
| 2026 Q1 | 18,938,098 | $62,116,945 | +$6,551,954 | $3.28 | 41 |
| 2025 Q4 | 16,651,600 | $124,888,014 | +$2,765,695 | $7.50 | 34 |
| 2025 Q3 | 16,282,884 | $54,051,121 | +$296,694 | $3.32 | 27 |
| 2025 Q2 | 15,248,594 | $46,050,393 | +$442,513 | $3.02 | 29 |
| 2025 Q1 | 16,047,858 | $49,105,818 | +$23,516,169 | $3.06 | 29 |
| 2024 Q4 | 8,368,639 | $19,916,902 | +$2,876,004 | $2.38 | 25 |
| 2024 Q3 | 7,107,091 | $20,255,014 | +$3,161,741 | $2.85 | 19 |
| 2024 Q2 | 5,990,280 | $17,670,609 | +$7,170,223 | $2.95 | 21 |
| 2024 Q1 | 3,559,240 | $10,429,392 | -$189,496 | $2.93 | 22 |
| 2023 Q4 | 3,624,342 | $9,059,295 | -$247,783 | $2.50 | 24 |
| 2023 Q3 | 3,718,862 | $11,617,455 | +$11,614,005 | $3.12 | 26 |
| 2023 Q2 | 15,000 | $3,450 | +$3,450 | $0.23 | 1 |